ADC Therapeutics SA
ADCT3.700USD
-0.250-6.31%
종가 03/27, 16:00（ET）시세는 15분 지연됩니다
283.85M시가총액
손실P/E TTM
자세한 내용은 ADC Therapeutics SA 회사
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
ADC Therapeutics SA 정보
종목 코드 ADCT
회사 이름ADC Therapeutics SA
상장일May 15, 2020
CEOMallik (Ameet)
직원 수263
유형Ordinary Share
회계 연도 종료May 15
주소Biopole
도시EPALINGES
증권 거래소NASDAQ OMX NASDAQ Basic NYSE
국가Switzerland
우편 번호1066
전화41216530200
웹사이트https://adctherapeutics.com/
종목 코드 ADCT
상장일May 15, 2020
CEOMallik (Ameet)
ADC Therapeutics SA의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
2.11M
+37.75%
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.58M
+1.57%
Mr. Mohamed Zaki, M.D., Ph.D.
Mr. Mohamed Zaki, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
861.86K
+30.24%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
597.29K
+41.14%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
573.04K
+45.63%
Dr. Peter Hug, Ph.D.
Dr. Peter Hug, Ph.D.
Non-Executive Vice Chairman of the Board, Lead Independent Director
Non-Executive Vice Chairman of the Board, Lead Independent Director
180.50K
+20.97%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Independent Director
Non-Executive Independent Director
134.98K
+27.72%
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
99.40K
+27.57%
Mr. Robert W. (Bob) Azelby
Mr. Robert W. (Bob) Azelby
Non-Executive Independent Director
Non-Executive Independent Director
55.26K
+49.58%
Mr. Timothy P. (Tim) Coughlin, CPA
Mr. Timothy P. (Tim) Coughlin, CPA
Director
Director
40.00K
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
2.11M
+37.75%
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.58M
+1.57%
Mr. Mohamed Zaki, M.D., Ph.D.
Mr. Mohamed Zaki, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
861.86K
+30.24%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
597.29K
+41.14%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
573.04K
+45.63%
Dr. Peter Hug, Ph.D.
Dr. Peter Hug, Ph.D.
Non-Executive Vice Chairman of the Board, Lead Independent Director
Non-Executive Vice Chairman of the Board, Lead Independent Director
180.50K
+20.97%
수익 분석
기업이 아직 관련 데이터를 공개하지 않았습니다.
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Thu, Feb 19
마지막 업데이트: Thu, Feb 19
주주
주주 유형
주주
주주
비율
Redmile Group, LLC
12.33%
TCG Crossover Management, LLC
8.97%
HPWH TH AG
6.82%
Prosight Capital
6.67%
OrbiMed Advisors, LLC
4.58%
기타
60.62%
주주
주주
비율
Redmile Group, LLC
12.33%
TCG Crossover Management, LLC
8.97%
HPWH TH AG
6.82%
Prosight Capital
6.67%
OrbiMed Advisors, LLC
4.58%
기타
60.62%
주주 유형
주주
비율
Investment Advisor/Hedge Fund
23.59%
Investment Advisor
19.20%
Hedge Fund
15.96%
Corporation
6.82%
Individual Investor
6.09%
Research Firm
5.00%
Private Equity
4.58%
Bank and Trust
0.48%
Pension Fund
0.11%
기타
18.16%
기관 주식 보유
마지막 업데이트: Mon, Dec 8
마지막 업데이트: Mon, Dec 8
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
191
72.94M
63.83%
-1.48K
2025Q3
203
72.94M
76.75%
+266.41K
2025Q2
196
72.67M
64.60%
+13.50M
2025Q1
198
59.17M
80.56%
-20.65M
2024Q4
201
60.84M
78.41%
+1.63M
2024Q3
204
59.22M
80.70%
+2.20M
2024Q2
196
56.12M
64.88%
+18.35M
2024Q1
159
35.17M
75.47%
-27.30M
2023Q4
158
34.44M
76.49%
-6.23M
2023Q3
162
40.67M
76.05%
-5.62M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Redmile Group, LLC
15.67M
12.65%
--
--
Sep 30, 2025
TCG Crossover Management, LLC
1.39M
1.12%
+1.39M
--
Sep 30, 2025
HPWH TH AG
8.67M
7%
-1.12M
-11.42%
May 15, 2025
Prosight Capital
7.47M
6.03%
-3.00M
-28.62%
Sep 30, 2025
OrbiMed Advisors, LLC
5.91M
4.77%
--
--
Sep 30, 2025
Nantahala Capital Management, LLC
2.27M
1.83%
--
--
Sep 30, 2025
Point72 Asset Management, L.P.
8.14M
6.57%
+371.99K
+4.79%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
3.99M
3.22%
-69.14K
-1.70%
Sep 30, 2025
Oaktree Capital Management, L.P.
4.41M
3.56%
+392.78K
+9.78%
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
iShares Micro-Cap ETF
0.06%
SPDR S&P International Small Cap ETF
0.04%
iShares Biotechnology ETF
0.03%
iShares Russell 2000 Growth ETF
0.02%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 ETF
0.01%
Fidelity Enhanced Small Cap ETF
0%
더 보기
iShares Micro-Cap ETF
비율0.06%
SPDR S&P International Small Cap ETF
비율0.04%
iShares Biotechnology ETF
비율0.03%
iShares Russell 2000 Growth ETF
비율0.02%
ProShares UltraPro Russell2000
비율0.01%
ProShares Hedge Replication ETF
비율0.01%
Proshares Ultra Russell 2000
비율0.01%
Global X Russell 2000 ETF
비율0.01%
iShares Russell 2000 ETF
비율0.01%
Fidelity Enhanced Small Cap ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
